Lakefront Biotherapeutics (GLPGF) Non-Current Assets (2013 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Non-Current Assets for 14 consecutive years, with $364.9 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Non-Current Assets fell 36.88% year-over-year to $364.9 million in Q1 2026; TTM through Mar 2026 was $1.8 billion, a 34.28% decrease from a year earlier, with the FY2025 full-year figure at $369.5 million, down 57.12% from the prior year.
• Non-Current Assets was $364.9 million for Q1 2026 at Lakefront Biotherapeutics, down from $380.7 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $850.9 million in Q4 2024 and troughed at -$4317.8 billion in Q4 2022.
• A 5-year average of -$331.6 billion and a median of $533.5 million in 2023 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets surged 100.01% in 2023 and plunged 55.26% in 2025, its largest moves.
• Over 5 years, Non-Current Assets stood at -$4317.8 billion in 2022, then soared by 100.01% to $533.5 million in 2023, then soared by 59.5% to $850.9 million in 2024, then sank by 55.26% to $380.7 million in 2025, then fell by 4.15% to $364.9 million in 2026.
• The last three Non-Current Assets figures came in at $364.9 million (Q1 2026), $380.7 million (Q4 2025), and $409.0 million (Q3 2025), per Business Quant data.